Medicare Enrolled

Dr. Ben Yan, M.D.

Hematology & Oncology · Wyoming, MI
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
5950 METRO WAY SW, Wyoming, MI 49519
6162528100
In practice since 2007 (19 years)
NPI: 1417153701 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Yan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Yan? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Yan

Dr. Ben Yan is a hematology & oncology specialist in Wyoming, MI, with 19 years of NPI registration. Based on federal Medicare data, Dr. Yan performed 1,815 Medicare services across 556 unique beneficiaries.

Between the years covered by Open Payments, Dr. Yan received a total of $8,638 from 53 pharmaceutical and/or device companies across 395 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Yan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 31% volume in MI $8,638 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,815
Medicare services
Top 31% in MI for hematology & oncology
556
Unique beneficiaries
$58
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~96 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 900 $18 $38
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
346 $88 $311
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
160 $133 $437
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
110 $94 $257
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
102 $57 $221
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
57 $61 $179
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
55 $135 $498
New patient office visit, complex (60-74 min) 29 $161 $539
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
26 $121 $409
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
16 $9 $35
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
14 $98 $433
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$8,638
Total received (2018-2024)
Avg $1,440/year across 6 years
Top 20% in MI for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
53
Companies
395
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,083 (93.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$555 (6.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$716
2023
$1,549
2022
$1,314
2020
$578
2019
$2,515
2018
$1,967

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$198
PFIZER INC.
$96
Daiichi Sankyo Inc.
$69
AstraZeneca Pharmaceuticals LP
$50
ABBVIE INC.
$33
GlaxoSmithKline, LLC.
$32
Lilly USA, LLC
$31
GENZYME CORPORATION
$26
Gilead Sciences, Inc.
$26
Eisai Inc.
$24
Merck Sharp & Dohme LLC
$20
Karyopharm Therapeutics Inc.
$20
EMD Serono, Inc.
$20
E.R. Squibb & Sons, L.L.C.
$20
Bayer Healthcare Pharmaceuticals Inc.
$17
Pharmacosmos Therapeutics Inc.
$17
Alexion Pharmaceuticals, Inc.
$17
Top 3 companies account for 50.7% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$998
Lilly USA, LLC
$776
Genentech USA, Inc.
$739
AstraZeneca Pharmaceuticals LP
$672
PFIZER INC.
$535
E.R. Squibb & Sons, L.L.C.
$483
GENZYME CORPORATION
$447
Janssen Biotech, Inc.
$353
Merck Sharp & Dohme Corporation
$338
Daiichi Sankyo Inc.
$314
Amgen Inc.
$217
Merck Sharp & Dohme LLC
$216
Bayer HealthCare Pharmaceuticals Inc.
$196
Incyte Corporation
$170
Gilead Sciences, Inc.
$127
Seattle Genetics, Inc.
$126
GlaxoSmithKline, LLC.
$111
Bayer Healthcare Pharmaceuticals Inc.
$103
EMD Serono, Inc.
$102
SANOFI-AVENTIS U.S. LLC
$99
Regeneron Healthcare Solutions, Inc.
$96
TerSera Therapeutics LLC
$86
Takeda Pharmaceuticals U.S.A., Inc.
$84
Foundation Medicine, Inc.
$83
Exelixis Inc.
$80
Eisai Inc.
$80
Kite Pharma, Inc.
$74
EISAI INC.
$70
Boehringer Ingelheim Pharmaceuticals, Inc.
$69
Pharmacosmos Therapeutics Inc.
$66
Pharmacyclics LLC, An AbbVie Company
$56
Mirati Therapeutics, Inc.
$52
JAZZ PHARMACEUTICALS INC.
$51
Janssen Pharmaceuticals, Inc
$51
Seagen Inc.
$50
Alexion Pharmaceuticals, Inc.
$44
AVEO Pharmaceuticals, Inc.
$40
Astellas Pharma US Inc
$38
GE HealthCare
$34
ABBVIE INC.
$33
Taiho Oncology, Inc.
$33
Dova Pharmaceuticals
$32
Stemline Therapeutics Inc.
$25
Blueprint Medicines Corporation
$23
Carl Zeiss Meditec, Inc.
$21
TESARO, Inc.
$20
CTI BioPharma Corp.
$20
Karyopharm Therapeutics Inc.
$20
Agios Pharmaceuticals, Inc.
$18
Puma Biotechnology, Inc.
$18
Array BioPharma Inc.
$17
MEDIVATION FIELD SOLUTIONS LLC
$17
Verastem, Inc.
$15
Top 3 companies account for 29.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALUNBRIG · AYVAKIT · Alecensa · Avastin · BAVENCIO · BLENREP · BOSULIF · Balversa · Bavencio · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELIQUIS · ELITEK · EMEND · ENHERTU · ERBITUX · Enhertu · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · Fabhalta · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · IORT · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONOFERRIC · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OPDIVO · Orserdu · PIQRAY · PLUVICTO · PROMACTA · Perjeta · SANDOSTATIN · SARCLISA · SCEMBLIX · SOLIRIS · SUTENT · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · TUKYSA · Trodelvy · ULTOMIRIS · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XPOVIO · XTANDI · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in Wyoming?
Compare hematology & oncology specialists in the Wyoming area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
24
Per 100K population
3.6
County median income
$80,390
Nearest hospital
UNIVERSITY OF MICHIGAN HEALTH - WEST
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Yan is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 20% of MI peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Yan experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Yan performed 900 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Yan receive payments from pharmaceutical companies?
Yes. Dr. Yan received a total of $8,638 from 53 companies across 395 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Yan's costs compare to other hematology & oncology specialists in Wyoming?
Dr. Yan's average Medicare payment per service is $58. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Yan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →